Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Summary

Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2 Double-Expressor Diffuse Large B-cell Lymphoma.

Timeline

Start

2020-05-21

Primary completion

2023-01-10

Completion

2025-06-29

Publications

• Xu PP, Song YQ, Shen JZ, Cai QQ, Zhou H, Zhang LL, Xiang Y, Sun XH, Yang W, Yao ZH, Jing HM, Wen SJ, Jin J, Xue HW, Cen H, Ding KY, Jin ZM, Liu LH, Xing XJ, Li LF, Hou M, Liu L, Zhang MZ, Li WY, Bai O, Feng R, Zhu ZM, Wu HJ, Su LP, Gao L, Li F, Huang WR, Liu P, Yan XJ, Zhao Y, Su H, Zhao XL, Fu R, Liu H, Shi WY, Li HZ, Chen B, Ning ZQ, Zhu J, Zhao WL. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. JAMA. 2026 May 19;335(19):1684-1693. doi: 10.1001/jama.2026.4199.

Drugs

Indications